Specifications TableSubjectToxicologySpecific subject areaEpigeneticsType of dataTables and GraphHow data were acquiredMicroplate reader (Fisher Scientific Multiscan FC)Data formatRaw and analyzedParameters for data collectionOn postnatal day 35, mice were pipet-fed tocopherol-stripped corn oil (vehicle control; alone or dibutyl phthalate dissolved in oil at 10 μg/kg/day, 100 μg/kg/day, and 1000 mg/kg/day. At the end of 10, 20, or 30 days of daily oral dosing, animals were sacrificed within 1--2 hours after the final dose.Description of data collectionNuclear extracts from mice uterus were subjected to a commercial DNMT activity ELISA assay. DNMT activity, which in this assay is proportional to the optical density measured, was detected by reading the absorbance generated by each sample using a microplate spectrophotometer at a wavelength of 450 nm.Data source locationCaguas, Puerto Rico, USAData accessibilityData is provided in this article**Value of the Data**•These data on the effect of oral DBP exposure on uterine DNA methyltransferase activity provide insight into the mechanisms of action of this endocrine-disrupting chemical.•These data will benefit the fields of reproductive biology and toxicology by enhancing understanding of how environmentally-induced epigenetic alterations can affect normal uterine function, reproduction, and the development of several complex diseases that compromise women\'s health.•These data highlight the potential negative effects of phthalates on epigenetic regulation of uterine function; thus, they will stimulate the formulation of novel hypotheses and experiments aimed at elucidating the role of phthalate exposures on the development of epigenetically-driven uterine diseases.

1. Data description {#sec1}
===================

In this report, we present data on the activity of uterine DNA methyltransferase in CD-1 mice treated with tocopherol-stripped corn oil (vehicle) or DBP dissolved in oil at 10 μg/kg/day, 100 μg/kg/day and 1000 mg/kg/day for 10, 20, and 30 days \[[@bib1], [@bib2]\]. DBP significantly disrupted the activity of DNMT at 20 and 30 days as compared with vehicle. These effects were not seen at 10 days. At 20 days of DBP exposure, we observed an increase on DNMT activity in the uteri of mice treated with DBP at 100 μg/kg/day. This effect of DBP exposure at 100 μg/kg/day was dose specific as it disappeared with increasing dose. Interestingly, at 30 days a reduction in DNMT activity was observed in all doses as compared with vehicle ([Fig. 1](#fig1){ref-type="fig"}). The raw data, terminal estrous cycle stage, and normalized values (OD and blank averages) of this study separated by time points are shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}.Fig. 1Effects of oral exposure to DBP on uterine DNA Methyltransferase (DNMT) activity (n = 8/treatment/timepoint; total n = 96). DNMT activity in uteri was expressed as the mean value ± standard error (SEM). CD-1 were dosed as described in Material and Methods for 10 days (**A**), 20 days (**B**), and 30 days (**C**) with DBP. Asterisks (\*) indicate statistical differences versus vehicle (\*\*p \< 0.05), (\*\*\*p \< 0.001) and (\*\*\*\*p \< 0.0001).Fig. 1Table 1DNMT activity raw data: Treatment for 10 days with DBP.Table 1CycleTreatmentAverage OD 450OD-BlankDNMT ActivityMvehicle0.136950.102855.143Dvehicle0.140.10595.295Evehicle0.252050.2179510.898Dvehicle0.14720.11315.655Dvehicle0.242250.2081510.408Dvehicle0.160950.126856.343Dvehicle0.197150.163058.153Dvehicle0.23060.19659.825P10 μg/kg/day0.18440.15037.515D10 μg/kg/day0.253850.2197510.988D10 μg/kg/day0.19170.15767.880P10 μg/kg/day0.11520.08114.055M10 μg/kg/day0.086550.052452.623M10 μg/kg/day0.128950.094854.743D10 μg/kg/day0.194650.160558.028P10 μg/kg/day0.108650.074553.728M100 μg/kg/day0.154150.120056.003D100 μg/kg/day0.178950.144857.243D100 μg/kg/day0.135550.101455.073D100 μg/kg/day0.20350.16948.470D100 μg/kg/day0.274950.2408512.043M100 μg/kg/day**\*\*\*\*\*\***D100 μg/kg/day0.17470.14067.030E100 μg/kg/day0.180550.146457.323D1000 mg/kg/day0.276150.2420512.103D1000 mg/kg/day0.18940.15537.765D1000 mg/kg/day0.150950.116855.843D1000 mg/kg/day0.10870.07463.730D1000 mg/kg/day0.15180.11775.885P1000 mg/kg/day0.1190.08494.245D1000 mg/kg/day0.20340.16938.465D1000 mg/kg/day0.121650.170458.523[^1][^2][^3][^4][^5]Table 2DNMT activity raw data: Treatment for 20 days with DBP.Table 2CycleTreatmentAverage OD 450OD-BlankDNMT ActivityPvehicle0.204550.170458.523Mvehicle0.26780.233711.685Mvehicle0.21550.18149.070Dvehicle0.196850.162758.138Pvehicle0.21020.17618.805Mvehicle0.20760.17358.675Pvehicle0.215650.181559.078Evehicle0.09430.06023.010P10 μg/kg/day0.359850.3257516.288P10 μg/kg/day0.13490.10085.040P10 μg/kg/day0.115350.081254.063E10 μg/kg/day\*\*\*\*\*\*P10 μg/kg/day0.123950.089854.493P10 μg/kg/day0.14910.1155.750E10 μg/kg/day0.246250.2121510.608P/E10 μg/kg/day0.23110.1979.850P100 μg/kg/day0.483450.4834524.1725P100 μg/kg/day0.33310.29914.950E100 μg/kg/day0.481050.4469522.348P/E100 μg/kg/day0.43480.400720.035P100 μg/kg/day0.37360.339516.975P100 μg/kg/day0.37040.336316.815P100 μg/kg/day0.257550.2234511.173D100 μg/kg/day0.3910.356917.845P1000 mg/kg/day0.390150.3560517.803P1000 mg/kg/day0.194350.160258.013P1000 mg/kg/day0.192350.158257.913P/E1000 mg/kg/day0.283650.2495512.478P1000 mg/kg/day0.17340.13936.965P1000 mg/kg/day0.199350.165258.263E1000 mg/kg/day0.22990.19589.790D1000 mg/kg/day0.12450.09044.520[^6][^7][^8][^9][^10]Table 3DNMT activity raw data: Treatment for 30 days with DBP.Table 3CycleTreatmentAverage OD 450OD-BlankDNMT ActivityPvehicle0.29860.264513.225Pvehicle0.27940.245312.265Dvehicle0.222250.188159.408Dvehicle0.350550.3164515.823Pvehicle0.281250.2471512.358Pvehicle0.28690.252812.640Dvehicle0.23440.200310.015Dvehicle0.162350.128256.413P10 μg/kg/day0.127850.093754.688P10 μg/kg/day0.217250.183159.158P10 μg/kg/day0.22040.18639.315E10 μg/kg/day0.201950.167858.393D10 μg/kg/day0.206450.172358.618P/E10 μg/kg/day\*\*\*\*\*\*P10 μg/kg/day0.17630.14227.110P10 μg/kg/day0.3370.302915.145E100 μg/kg/day0.22550.19149.570P100 μg/kg/day0.24230.208210.410P100 μg/kg/day0.2320.19799.895P100 μg/kg/day0.1350.10095.045P100 μg/kg/day0.357050.3229516.148E100 μg/kg/day0.358450.3243516.218P100 μg/kg/day0.181750.147657.383E100 μg/kg/day0.172150.138056.903P1000 mg/kg/day0.1880.15397.695E1000 mg/kg/day0.13590.10185.090P1000 mg/kg/day0.16060.12656.325P1000 mg/kg/day0.159350.125256.263D1000 mg/kg/day0.12670.09264.630E1000 mg/kg/day0.2530.218910.945P1000 mg/kg/day0.55540.521326.065D1000 mg/kg/day0.13930.10525.260[^11][^12][^13][^14][^15]

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Animal model {#sec2.1}
-----------------

Female CD-1 mice (28 days old) were purchased from Charles River Laboratories (Charles River, CA). Animals were housed at the University of Illinois College of Veterinary Medicine Central Animal Facility with food and water provided at libitum, temperature set at 22 ± 1 °C, and 12L:12D cycles. Prior to entering the study, animals were allowed to acclimate to the animal facilities for at least 48 h. Animals were dosed as described below and euthanized by CO~2~ inhalation followed by cervical dislocation. The use of animals in these studies was approved by the University of Illinois Institutional Animal Care and Use Committee and conformed to the Guide for the Care and Use of Experimental Animals \[[@bib3]\].

2.2. In vivo exposure to Dibutyl Phthalate (DBP) and tissue collection {#sec2.2}
----------------------------------------------------------------------

On postnatal day 35, mice (n = 8/treatment; total = 32 mice per time point) were pipet-fed tocopherol-stripped corn oil (vehicle control; MP Biomedicals, Solon, OH) alone or dibutyl phthalate (99.6% purity, Sigma-Aldrich, St. Louis, MO) dissolved in oil at 10 μg/kg/day, 100 μg/kg/day, and 1000 mg/kg/day as previously described \[[@bib4]\]. These doses were selected based on reported intake estimates in the general population (7--10 μg/kg/day) \[[@bib5]\] and in medically and occupationally exposed subjects (up to 233 μg/kg/day) \[[@bib2],[@bib6]\]. The highest dose of 1000 mg/kg/day was included to compare to exposure levels typically used in classical toxicity testing. Weights, estrous cyclicity, and overall health were recorded daily throughout the dosing period. At the end of 10, 20, or 30 days of daily oral dosing, animals were sacrificed within 1--2 hours after the final dose. The stage of the estrous cycle was recorded, and the uteri dissected, weighed and frozen.

2.3. Estrous cyclicity {#sec2.3}
----------------------

Terminal estrous cycle stage was determined by vaginal smearing prior to euthanasia. Briefly, mice were restrained gently and 20 μL of sterile-filtered PBS was used to perform a vaginal washing. Vaginal washings were visualized unstained under an inverted microscope without knowledge of treatment \[[@bib7]\].

2.4. Nuclear extractions {#sec2.4}
------------------------

Frozen uteri were weighed and cut into small pieces (1--2 mm^3^) with a scalpel before homogenization with a Bullet Blender Storm 24 (Next Advance, Averill Park, NY). The homogenate was resuspended in lysis buffer containing 2% SDS in PBS and supplemented with proteinase and phosphatase inhibitors. Nuclear extracts were isolated using EpiQuik™ Nuclear Extraction Kit (Epigentek, Brooklyn, NY). Total protein concentration was quantified using Bio-Rad protein assay (Valencia, CA). BSA was used to generate a standard curve.

2.5. DNMT activity {#sec2.5}
------------------

EpiQuik DNMT Activity/Inhibition ELISA Easy Kit™ immunoassay (Epigentek, Brooklyn, NY) was used to measure total DNMT activity using nuclear extracts from frozen uterine tissues. This assay provides information on global DNMT activity including DNMTs 1, 3A, 3B, 2 and 3L without distinction. In brief, nuclear extracts (20 μg) were added to the wells on the EpiQuik DNMT Activity/Inhibition ELISA Easy Kit™ immunoassay 96-well plate and incubated for 1 hour according to the manufacturer\'s instructions. Colorimetric analysis was conducted using a microplate reader. The ratio of methylated DNA, which is proportional to enzyme activity, was measured at a wavelength of 450 nm. The activity of DNMT enzymes is proportional to the optical density intensity measured. DNMT activity was calculated using the following formula:$$DNMTActivity\ \left\langle OD\text{|}h\text{|}mg \right\rangle = \frac{Sample\ OD - Blank\ OD}{Protein\ amount\ ug \times hour\ } \times 1000$$

Two technical replicates were conducted for validation purposes.

2.6. Statistical analyses {#sec2.6}
-------------------------

Parametric analysis of variance (ANOVA) with Dunnett\'s post-test were conducted to determine statistical significance of differences among study groups using GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA). Statistical significance was set at p \< 0.05.
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